Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the use of biologic agents in the first-line treatment of metastatic colorectal cancer
- Summarize the use of adjuvant therapy in colorectal cancer
- Identify factors that contribute to improved prognosis in colorectal cancer
- Report recent findings in advanced pancreatic cancer
- Describe results of important new clinical studies relevant to the treatment of hepatocellular carcinoma and esophagogastric cancers
Topics covered include:
- Cetuximab Plus FOLFIRI Improves Progression-Free Survival in Patents With Previously Untreated Metastatic Colorectal Cancer (CRYSTAL Study)
- Bevacizumab Added to Standard Combination Therapies Improves Progression-Free Survival in Previously Untreated Metastatic Colorectal Cancer
- Chemotherapy-Free Interval Not Recommended Following Oxaliplatin-Based Chemotherapy in Treatment of Metastatic Colorectal Cancer
- Combination Treatment With Active Cytotoxics for Advanced Colorectal Cancer Does Not Prolong Survival vs Sequential Therapy
- Extending First-Line Bevacizumab Treatment Past First Disease Progression May Improve Survival Outcomes for Patients With Metastatic Colorectal Cancer
- Cetuximab May Improve Quality of Life When Added to Standard Treatments in Patients With Advanced Colorectal Cancer
- Biomarkers and Number of Circulating Tumor Cells Predict Treatment Outcome in Patients With Metastatic Colorectal Cancer
- Perioperative FOLFOX4 Increases Progression-Free Survival in Metastatic Colorectal Cancer Patients With Resectable Liver Metastases
- Phase III MOSAIC Follow-up Data Confirm Survival Benefit for Adjuvant FOLFOX4 in Stage III Colon Cancer
- “Western” Diets Associated With Poor Outcomes for Patients With Established, Treated Stage III Colon Cancer
- Neither Bevacizumab nor Cetuximab Confer Survival Advantage in Advanced Pancreatic Cancer
- FOLFIRINOX Active as First-Line Therapy for Metastatic Pancreatic Adenocarcinoma
- Sorafenib Prolongs Survival in Advanced Hepatocellular Carcinoma
- Preoperative Treatment With 5-Fluorouracil Plus Cisplatin Improves Survival in Resectable Adenocarcinoma of Stomach and Lower Esophagus
- S-1 Effective as Single-Agent, or Combined With Platinum Drugs, in First-Line Treatment of Advanced Gastric Cancer